Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963383 | 0.80 | MEN1 (0.49) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL4154483 | 0.74 | APLNR (0.54) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL10640944 | 0.71 | KDM4E (0.53) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL27396041 | 0.71 | APLNR (0.51) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL27396042 | 0.71 | APLNR (0.48) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL23120457 | 0.70 | ALDH1A1 (0.49) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL1732274 | 0.70 | MEN1 (0.43) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL19710911 | 0.70 | ALDH1A1 (0.44) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL9804694 | 0.70 | KDM4E (0.61) | APLNRALDH1A1TSHRKDM4EMAPT | |
| SCHEMBL8373325 | 0.69 | MTNR1A (0.52) | APLNRALDH1A1TSHRKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | disclosed |
| EP-1492780-A1 | 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
| WO-2003082841-A1 | 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | APLNR 1606/4885ALDH1A1 2368/4885TSHR 1221/4885 |
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | APLNR 2463/4885ALDH1A1 2690/4885TSHR 2240/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | APLNR 2601/4885ALDH1A1 4174/4885TSHR 1291/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | APLNR 1631/4885ALDH1A1 2575/4885TSHR 1057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.